Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

766 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antifungal Stewardship in Hematology: Reflection of a Multidisciplinary Group of Experts.
Michallet M, Sobh M, Deray G, Gangneux JP, Pigneux A, Larrey D, Ribaud P, Mira JP, Nivoix Y, Yakoub-Agha I, Timsit JF, Alfandari S, Herbrecht R. Michallet M, et al. Among authors: timsit jf. Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):35-45. doi: 10.1016/j.clml.2020.08.010. Epub 2020 Aug 18. Clin Lymphoma Myeloma Leuk. 2021. PMID: 32958431 Review.
Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.
Bailly S, Leroy O, Montravers P, Constantin JM, Dupont H, Guillemot D, Lortholary O, Mira JP, Perrigault PF, Gangneux JP, Azoulay E, Timsit JF. Bailly S, et al. Among authors: timsit jf. Intensive Care Med. 2015 Nov;41(11):1931-40. doi: 10.1007/s00134-015-4053-1. Epub 2015 Sep 14. Intensive Care Med. 2015. PMID: 26370688
Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study.
Leroy O, Bailly S, Gangneux JP, Mira JP, Devos P, Dupont H, Montravers P, Perrigault PF, Constantin JM, Guillemot D, Azoulay E, Lortholary O, Bensoussan C, Timsit JF; AmarCAND2 study group. Leroy O, et al. Among authors: timsit jf. Ann Intensive Care. 2016 Dec;6(1):2. doi: 10.1186/s13613-015-0103-7. Epub 2016 Jan 8. Ann Intensive Care. 2016. PMID: 26743881 Free PMC article.
Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
Jullien V, Azoulay E, Schwebel C, Le Saux T, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Cour M, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Wolff M, Timsit JF; EMPIRICUS Trial Study Group. Jullien V, et al. Among authors: timsit jf. J Antimicrob Chemother. 2017 Jan;72(1):181-189. doi: 10.1093/jac/dkw352. Epub 2016 Sep 8. J Antimicrob Chemother. 2017. PMID: 27609051 Free article. Clinical Trial.
Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Maubon D, Jullien V, Wolff M; EMPIRICUS Trial Group. Timsit JF, et al. JAMA. 2016 Oct 18;316(15):1555-1564. doi: 10.1001/jama.2016.14655. JAMA. 2016. PMID: 27706483 Clinical Trial.
Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units.
Montravers P, Perrigault PF, Timsit JF, Mira JP, Lortholary O, Leroy O, Gangneux JP, Guillemot D, Bensoussan C, Bailly S, Azoulay E, Constantin JM, Dupont H; AmarCAND2 Study Group. Montravers P, et al. Among authors: timsit jf. Clin Microbiol Infect. 2017 Feb;23(2):117.e1-117.e8. doi: 10.1016/j.cmi.2016.10.001. Epub 2016 Oct 13. Clin Microbiol Infect. 2017. PMID: 27746395 Free article.
Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: A post-hoc causal inference model using the AmarCAND2 study.
Bailly S, Leroy O, Azoulay E, Montravers P, Constantin JM, Dupont H, Guillemot D, Lortholary O, Mira JP, Perrigault PF, Gangneux JP, Timsit JF; AmarCAND2 Study Group. Bailly S, et al. Among authors: timsit jf. J Infect. 2017 Apr;74(4):408-417. doi: 10.1016/j.jinf.2016.12.016. Epub 2017 Jan 16. J Infect. 2017. PMID: 28104387 Free article.
Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial.
Cambau E, Durand-Zaleski I, Bretagne S, Brun-Buisson C, Cordonnier C, Duval X, Herwegh S, Pottecher J, Courcol R, Bastuji-Garin S; EVAMICA study team. Cambau E, et al. Intensive Care Med. 2017 Nov;43(11):1613-1625. doi: 10.1007/s00134-017-4766-4. Epub 2017 Apr 3. Intensive Care Med. 2017. PMID: 28374097 Free PMC article. Clinical Trial.
Clinical Impact of Antifungal Susceptibility, Biofilm Formation and Mannoside Expression of Candida Yeasts on the Outcome of Invasive Candidiasis in ICU: An Ancillary Study on the Prospective AmarCAND2 Cohort.
Gangneux JP, Cornet M, Bailly S, Fradin C, Féger C, Timsit JF, Leroy O, Sendid B, Bougnoux ME. Gangneux JP, et al. Among authors: timsit jf. Front Microbiol. 2018 Dec 11;9:2907. doi: 10.3389/fmicb.2018.02907. eCollection 2018. Front Microbiol. 2018. PMID: 30619103 Free PMC article.
766 results